XORTX Therapeutics Inc. (NASDAQ:XRTX) Shares Shorted: Short Interest Down 48.3% in October

XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) saw a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 122,511 shares, a decrease of 48.3% from the October 15th total of 237,048 shares. Approximately 7.2% of the shares of the stock are short sold. Based on an average daily volume of 58,359 shares, the short-interest ratio is presently 2.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Read Our Latest Stock Analysis on XRTX

XORTX Therapeutics Stock Performance

NASDAQ XRTX opened at $1.10 on Monday. XORTX Therapeutics has a 52-week low of $0.82 and a 52-week high of $3.60. The company has a market capitalization of $2.00 million, a P/E ratio of -0.48 and a beta of 0.83. The company has a fifty day moving average of $1.47 and a 200-day moving average of $2.03.

XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last announced its earnings results on Friday, November 13th. The technology company reported ($0.21) earnings per share (EPS) for the quarter.

XORTX Therapeutics Company Profile

(Get Free Report)

XORTX Therapeutics Inc. (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases. XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.

See Also

Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.